Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
- Mar 5, 2024
- 2 min read
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.
WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET® drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has advanced ABBV-303 into the clinic," said Bill Haney, CEO and Dragonfly co-founder. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."
Additional information about the M24-122 Phase 1 trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT06158958).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:www.dragonflytx.comhttps://www.linkedin.com/company/dragonfly-therapeutics-inc./https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
This is a significant milestone — early-phase trials like this are where safety and initial effectiveness are tested, so dosing the first patient is a crucial step in moving a therapy forward. It’s impressive to see how collaborations like this aim to develop new immunotherapies targeting solid tumors, especially using advanced platforms like TriNKET® . Progress at this stage depends heavily on careful research, coordination, and long-term commitment. That idea of how structured effort and external expectations influence outcomes also connects more broadly to discussions by Mārtiņš Lauva , where awareness and pressure play a role in shaping results in a completely different field.
Doing thorough research is always important, and I found contenc to be a helpful resource with detailed information on related topics worth reading.
I recently came across ticket-satety while looking into different financial service platforms and found the content to be well-structured and easy to navigate.
This update about Dragonfly Therapeutics reaching a milestone in the AbbVie clinical trial shows how persistence and progress matter in any creative or scientific pursuit. It made me think about the journey authors go through when trying to bring a book to life from research and drafting to editing and finally finding the right place to share it. For many writers, a common early question is how to publish near me so they can connect with local presses, workshops, and community support as they refine their work and prepare for release.
Interesting to see how milestone achievements reward persistence and planning whether in clinical research or creative work like writing a book. When I was navigating my own publishing journey, connecting with a book publishing consultant helped me set realistic goals and track progress, much like a research roadmap. It made the process feel more manageable and purposeful. Curious if others have found structured guidance helpful when working toward their own long-term creative milestones?